非小细胞肺癌靶向治疗相关进展
Recent Advances in Targeted Therapies for Non-Small Cell Lung Cancer
摘要: 作为一种高发病率和高死亡率的常见的恶性肿瘤，肺癌对人类健康和生命造成巨大威胁。其中非小细胞肺癌在全部肺癌发病中占比达85%，尽管手术作为早期肺癌明确的治疗手段，但延缓恶化后复发率依旧很高。随着现代医疗技术不断发展，大量靶向药物涌现，并表现出可观的疗效。靶向药物与化疗、放疗以及免疫检查点抑制剂联用后，不仅增强了治疗的协同效应，对耐药性的抑制和逆转也都有一定效果，为非小细胞肺癌的治疗提供全新选择。
Abstract: Lung cancer, recognized as a prevalent malignant tumor with elevated rates of occurrence and mortality, presents a considerable danger to human health and well-being. Non-small cell lung cancer accounts for 85% of all lung cancer cases. Although surgery is the definitive treatment for early-stage lung cancer, recurrence rates remain high after disease stabilization. With the continuous advancement of modern medical technology, numerous targeted drugs have emerged, demonstrating considerable therapeutic efficacy. When combined with chemotherapy, radiotherapy, and immune checkpoint inhibitors, targeted drugs not only enhance synergistic therapeutic effects but also exhibit certain efficacy in suppressing and reversing drug resistance, offering novel treatment options for Non-small cell lung cancer.
文章引用：张扬, 沈蕾. 非小细胞肺癌靶向治疗相关进展[J]. 临床医学进展, 2026, 16(9): 534-549. https://doi.org/10.12677/acm.2026.1693077

参考文献

[1] Siegel, R.L., Kratzer, T.B., Giaquinto, A.N., Sung, H. and Jemal, A. (2025) Cancer Statistics, 2025. CA: A Cancer Journal for Clinicians, 75, 10-45.
https://doi.org/10.3322/caac.21871
[2] Yu, F., Zheng, S., Yu, C., Gao, S., Shen, Z., Nar, R., et al. (2025) KRAS Mutants Confer Platinum Resistance by Regulating ALKBH5 Posttranslational Modifications in Lung Cancer. Journal of Clinical Investigation, 135, e185149.
https://doi.org/10.1172/jci185149
[3] Li, M.S.C., Mok, K.K.S. and Mok, T.S.K. (2023) Developments in Targeted Therapy & Immunotherapy—How Non-Small Cell Lung Cancer Management Will Change in the Next Decade: A Narrative Review. Annals of Translational Medicine, 11, 358-358.
https://doi.org/10.21037/atm-22-4444
[4] Sun, H., Li, M., Huang, W., Zhang, J., Wei, S., Yang, Y., et al. (2025) Thoracic Radiotherapy Improves the Survival in Patients with EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial. Journal of Clinical Oncology, 43, 412-421.
https://doi.org/10.1200/jco.23.02075
[5] Cheng, Y., He, Y., Li, W., Zhang, H., Zhou, Q., Wang, B., et al. (2021) Osimertinib versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, a Randomized Study. Targeted Oncology, 16, 165-176.
https://doi.org/10.1007/s11523-021-00794-6
[6] Ramalingam, S.S., Vansteenkiste, J., Planchard, D., Cho, B.C., Gray, J.E., Ohe, Y., et al. (2020) Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 382, 41-50.
https://doi.org/10.1056/nejmoa1913662
[7] Ramalingam, S.S., Yang, J.C., Lee, C.K., Kurata, T., Kim, D., John, T., et al. (2018) Osimertinib as First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 36, 841-849.
https://doi.org/10.1200/jco.2017.74.7576
[8] Bak, M., Park, H., Lee, S., Lee, N., Ahn, M., Ahn, J.S., et al. (2025) The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population. Journal of Thoracic Oncology, 20, 167-176.
https://doi.org/10.1016/j.jtho.2024.10.003
[9] Le, X., Patel, J.D., Shum, E., Baik, C., Sanborn, R.E., Shu, C.A., et al. (2025) A Multicenter Open-Label Randomized Phase II Study of Osimertinib with and without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE Trial). Journal of Clinical Oncology, 43, 403-411.
https://doi.org/10.1200/jco.24.00533
[10] Planchard, D., Jänne, P.A., Cheng, Y., Yang, J.C., Yanagitani, N., Kim, S., et al. (2023) Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 389, 1935-1948.
https://doi.org/10.1056/nejmoa2306434
[11] Saito, R., Sugawara, S., Ko, R., Azuma, K., Morita, R., Maemondo, M., et al. (2023) Phase 2 Study of Osimertinib in Combination with Platinum and Pemetrexed in Patients with Previously Untreated EGFR-Mutated Advanced Non-Squamous Non-Small Cell Lung Cancer: The OPAL Study. European Journal of Cancer, 185, 83-93.
https://doi.org/10.1016/j.ejca.2023.02.023
[12] Lu, S., Dong, X., Jian, H., Chen, J., Chen, G., Sun, Y., et al. (2022) AENEAS: A Randomized Phase III Trial of Aumolertinib versus Gefitinib as First-Line Therapy for Locally Advanced or Metastaticnon-Small-Cell Lung Cancer with EGFR Exon 19 Deletion or L858R Mutations. Journal of Clinical Oncology, 40, 3162-3171.
https://doi.org/10.1200/jco.21.02641
[13] Niu, H., Song, F., Zhou, X., Jin, Q., Liu, Y., Luo, B., et al. (2025) Severe Hypotension Induced by Almonertinib: A Case Report with Literature Review and Clinical Insights. Frontiers in Oncology, 15, Article 1566768.
https://doi.org/10.3389/fonc.2025.1566768
[14] Zhou, Q., Hu, Z., Li, X. and Tang, X. (2023) Almonertinib-Induced Interstitial Lung Disease in a Lung Adenocarcinoma Patient Complicated with Interstitial Lung Abnormality. BMC Pulmonary Medicine, 23, Article No. 79.
https://doi.org/10.1186/s12890-023-02367-x
[15] Felip, E., Cho, B.C., Gutiérrez, V., Alip, A., Besse, B., Lu, S., et al. (2024) Amivantamab Plus Lazertinib versus Osimertinib in First-Line EGFR-Mutant Advanced Non-Small-Cell Lung Cancer with Biomarkers of High-Risk Disease: A Secondary Analysis from Mariposa. Annals of Oncology, 35, 805-816.
https://doi.org/10.1016/j.annonc.2024.05.541
[16] Shi, Y., Chen, G., Wang, X., Liu, Y., Wu, L., Hao, Y., et al. (2022) Central Nervous System Efficacy of Furmonertinib (AST2818) versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results from the FURLONG Study. Journal of Thoracic Oncology, 17, 1297-1305.
https://doi.org/10.1016/j.jtho.2022.07.1143
[17] Sa, H., Shi, Y., Ding, C. and Ma, K. (2023) A Real-World Study of the Efficacy and Safety of Furmonertinib for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Journal of Cancer Research and Clinical Oncology, 149, 7729-7742.
https://doi.org/10.1007/s00432-023-04726-x
[18] Hou, J., Li, H., Ma, S., He, Z., Yang, S., Hao, L., et al. (2022) EGFR Exon 20 Insertion Mutations in Advanced Non-Small-Cell Lung Cancer: Current Status and Perspectives. Biomarker Research, 10, Article No. 21.
https://doi.org/10.1186/s40364-022-00372-6
[19] Yang, G., Li, J., Xu, H., Sun, Y., Liu, L., Li, H., et al. (2021) Osimertinib for Chinese Advanced Non-Small Cell Lung Cancer Patients Harboring Diverse EGFR Exon 20 Insertion Mutations. Lung Cancer, 152, 39-48.
https://doi.org/10.1016/j.lungcan.2020.11.027
[20] Yang, G., Li, J., Xu, H., Yang, Y., Yang, L., Xu, F., et al. (2020) EGFR Exon 20 Insertion Mutations in Chinese Advanced Non-Small Cell Lung Cancer Patients: Molecular Heterogeneity and Treatment Outcome from Nationwide Real-World Study. Lung Cancer, 145, 186-194.
https://doi.org/10.1016/j.lungcan.2020.03.014
[21] Shi, Y., Chen, G., Wang, X., Liu, Y., Wu, L., Hao, Y., et al. (2024) Patient-Reported Outcomes for the Phase 3 FURLONG Study of Furmonertinib versus Gefitinib as First-Line Therapy for Chinese Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer. The Lancet Regional Health—Western Pacific, 48, Article ID: 101122.
https://doi.org/10.1016/j.lanwpc.2024.101122
[22] Luping, Z., Cheng, Z., Pan, L. and Xu, X. (2025) An Atypical Case of Acute Thrombocytopenia Induced by Rivaroxaban in a Patient with NSCLC Undergoing Furmonertinib Treatment. Asian Journal of Surgery, 48, 1327.
https://doi.org/10.1016/j.asjsur.2024.08.146
[23] Wang, Z., Yu, Z., Fang, L., An, J., Xue, C., Zhou, X., et al. (2025) Effect of Furmonertinib on the Pharmacokinetics of Rivaroxaban or Apixaban in Vivo. Journal of Chromatography B, 1251, Article ID: 124425.
https://doi.org/10.1016/j.jchromb.2024.124425
[24] Cho, B.C., Ahn, M., Kang, J.H., Soo, R.A., Reungwetwattana, T., Yang, J.C., et al. (2023) Lazertinib versus Gefitinib as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results from Laser301. Journal of Clinical Oncology, 41, 4208-4217.
https://doi.org/10.1200/jco.23.00515
[25] Ahn, M., Han, J., Lee, K.H., Kim, S., Kim, D., Lee, Y., et al. (2019) Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer: Results from the Dose Escalation and Dose Expansion Parts of a First-In-Human, Open-Label, Multicentre, Phase 1-2 Study. The Lancet Oncology, 20, 1681-1690.
https://doi.org/10.1016/s1470-2045(19)30504-2
[26] Lee, S., Choi, J. and Lee, S.Y. (2025) Lazertinib‐Induced Rhabdomyolysis in a Patient with Non‐Small Cell Lung Cancer: A Case Report. Respirology Case Reports, 13, e70105.
https://doi.org/10.1002/rcr2.70105
[27] Brazel, D. and Nagasaka, M. (2024) MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? Lung Cancer: Targets and Therapy, 15, 41-47.
https://doi.org/10.2147/lctt.s453974
[28] Cho, B.C., Felip, E., Spira, A.I., Girard, N., Lee, J., Lee, S., et al. (2023) LBA14 Amivantamab Plus Lazertinib vs Osimertinib as First-Line Treatment in Patients with EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Primary Results from MARIPOSA, a Phase III, Global, Randomized, Controlled Trial. Annals of Oncology, 34, S1306.
https://doi.org/10.1016/j.annonc.2023.10.062
[29] Mok, T., Camidge, D.R., Gadgeel, S.M., Rosell, R., Dziadziuszko, R., Kim, D., et al. (2020) Updated Overall Survival and Final Progression-Free Survival Data for Patients with Treatment-Naive Advanced Alk-Positive Non-Small-Cell Lung Cancer in the ALEX Study. Annals of Oncology, 31, 1056-1064.
https://doi.org/10.1016/j.annonc.2020.04.478
[30] Zhou, C., Kim, S., Reungwetwattana, T., Zhou, J., Zhang, Y., He, J., et al. (2019) Alectinib versus Crizotinib in Untreated Asian Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALESIA): A Randomised Phase 3 Study. The Lancet Respiratory Medicine, 7, 437-446.
https://doi.org/10.1016/s2213-2600(19)30053-0
[31] Rodriguez, R.R., Dindak, J., Kline, J. and Raj, M.S. (2023) Alectinib-Induced Rash Unresponsive to Desensitization: A Case Report and Literature Review. BMC Pulmonary Medicine, 23, Article No. 261.
https://doi.org/10.1186/s12890-023-02558-6
[32] Kim, D., Gadgeel, S., Gettinger, S.N., Riely, G.J., Oxnard, G.R., Mekhail, T., et al. (2022) Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab from a Phase 1b Study in Advanced Alk-Positive NSCLC. JTO Clinical and Research Reports, 3, Article ID: 100367.
https://doi.org/10.1016/j.jtocrr.2022.100367
[33] Watanabe, S., Sakai, K., Matsumoto, N., Koshio, J., Ishida, A., Abe, T., et al. (2022) Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory Alk-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). Cancers, 15, Article 204.
https://doi.org/10.3390/cancers15010204
[34] Lin, J.J., Schoenfeld, A.J., Zhu, V.W., Yeap, B.Y., Chin, E., Rooney, M., et al. (2020) Efficacy of Platinum/Pemetrexed Combination Chemotherapy in Alk-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. Journal of Thoracic Oncology, 15, 258-265.
https://doi.org/10.1016/j.jtho.2019.10.014
[35] Shi, Y., Chen, J., Zhang, H., Zhang, Z., Zhang, Y., Wang, Z., et al. (2023) Efficacy and Safety of Iruplinalkib (WX-0593) in Alk-Positive Crizotinib-Resistant Advanced Non-Small Cell Lung Cancer Patients: A Single-Arm, Multicenter Phase II Study (INTELLECT). BMC Medicine, 21, Article No. 72.
https://doi.org/10.1186/s12916-023-02738-5
[36] Shi, Y., Chen, J., Yang, R., Wu, H., Wang, Z., Yang, W., et al. (2024) Iruplinalkib (WX-0593) versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic Alk-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE). Journal of Thoracic Oncology, 19, 912-927.
https://doi.org/10.1016/j.jtho.2024.01.013
[37] Shaw, A.T., Bauer, T.M., de Marinis, F., Felip, E., Goto, Y., Liu, G., et al. (2020) First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine, 383, 2018-2029.
https://doi.org/10.1056/nejmoa2027187
[38] Solomon, B.J., Bauer, T.M., Mok, T.S.K., Liu, G., Mazieres, J., de Marinis, F., et al. (2023) Efficacy and Safety of First-Line Lorlatinib versus Crizotinib in Patients with Advanced, Alk-Positive Non-Small-Cell Lung Cancer: Updated Analysis of Data from the Phase 3, Randomised, Open-Label CROWN Study. The Lancet Respiratory Medicine, 11, 354-366.
https://doi.org/10.1016/s2213-2600(22)00437-4
[39] Lim, T.K.H., Skoulidis, F., Kerr, K.M., Ahn, M., Kapp, J.R., Soares, F.A., et al. (2023) KRAS G12C in Advanced NSCLC: Prevalence, Co-Mutations, and Testing. Lung Cancer, 184, Article ID: 107293.
https://doi.org/10.1016/j.lungcan.2023.107293
[40] Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M.R., et al. (2018) The Reactivity-Driven Biochemical Mechanism of Covalent KRASG12C Inhibitors. Nature Structural & Molecular Biology, 25, 454-462.
https://doi.org/10.1038/s41594-018-0061-5
[41] Hong, D.S., Fakih, M.G., Strickler, J.H., Desai, J., Durm, G.A., Shapiro, G.I., et al. (2020) KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. New England Journal of Medicine, 383, 1207-1217.
https://doi.org/10.1056/nejmoa1917239
[42] de Langen, A.J., Johnson, M.L., Mazieres, J., Dingemans, A.C., Mountzios, G., Pless, M., et al. (2023) Sotorasib versus Docetaxel for Previously Treated Non-Small-Cell Lung Cancer with KRASG12C Mutation: A Randomised, Open-Label, Phase 3 Trial. The Lancet, 401, 733-746.
https://doi.org/10.1016/s0140-6736(23)00221-0
[43] Dy, G.K., Govindan, R., Velcheti, V., Falchook, G.S., Italiano, A., Wolf, J., et al. (2023) Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreak 100. Journal of Clinical Oncology, 41, 3311-3317.
https://doi.org/10.1200/jco.22.02524
[44] Sun, J., Hwang, D.W., Ahn, J.S., Ahn, M. and Park, K. (2013) Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer. PLOS ONE, 8, e64816.
https://doi.org/10.1371/journal.pone.0064816
[45] Johnson, M., Younan, D., Kent, S.T., Mesa-Frias, M., Alan Brookhart, M., Balasubramanian, A., et al. (2024) Real-World Comparative Effectiveness of Sotorasib versus Docetaxel in Second Line and beyond among Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Lung Cancer, 197, Article ID: 107960.
https://doi.org/10.1016/j.lungcan.2024.107960
[46] Addeo, A., Banna, G.L., Metro, G. and Di Maio, M. (2019) Chemotherapy in Combination with Immune Checkpoint Inhibitors for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. Frontiers in Oncology, 9, Article 264.
https://doi.org/10.3389/fonc.2019.00264
[47] Wu, J., Xie, K., Zhang, Y., Zhang, W., Cheng, R., Zhang, Y., et al. (2025) RASON Promotes KRASG12C-Driven Tumor Progression and Immune Evasion in Non-Small Cell Lung Cancer. Journal of Experimental & Clinical Cancer Research, 44, Article No. 106.
https://doi.org/10.1186/s13046-025-03369-9
[48] Jänne, P.A., Riely, G.J., Gadgeel, S.M., Heist, R.S., Ou, S.I., Pacheco, J.M., et al. (2022) Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. New England Journal of Medicine, 387, 120-131.
https://doi.org/10.1056/nejmoa2204619
[49] Fell, J.B., Fischer, J.P., Baer, B.R., Blake, J.F., Bouhana, K., Briere, D.M., et al. (2020) Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 63, 6679-6693.
https://doi.org/10.1021/acs.jmedchem.9b02052
[50] Rosas, D., Barad, P., Wright, J. and Raez, L. (2026) KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. International Journal of Molecular Sciences, 27, Article 6455.
https://doi.org/10.3390/ijms27146455
[51] Negrao, M.V., Spira, A.I., Heist, R.S., Jänne, P.A., Pacheco, J.M., Weiss, J., et al. (2023) Intracranial Efficacy of Adagrasib in Patients from the KRYSTAL-1 Trial with KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases. Journal of Clinical Oncology, 41, 4472-4477.
https://doi.org/10.1200/jco.23.00046
[52] Yaeger, R., Uboha, N.V., Pelster, M.S., Bekaii-Saab, T.S., Barve, M., Saltzman, J., et al. (2024) Efficacy and Safety of Adagrasib Plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discovery, 14, 982-993.
https://doi.org/10.1158/2159-8290.cd-24-0217
[53] Zhang, J., Johnson, M., Barve, M., Bazhenova, L., McCarthy, M., Schwartz, R., et al. (2023) Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib. The Oncologist, 28, 287-296.
https://doi.org/10.1093/oncolo/oyad051
[54] Leeuwenberg, K.E., ter Heine, R., Gijtenbeek, J.M.M. and van den Heuvel, M.M. (2024) Polyradiculitis as a Neurological Complication Associated with Adagrasib: A Case Report. Case Reports in Oncology, 17, 1289-1293.
https://doi.org/10.1159/000541988
[55] Westover, D., Zugazagoitia, J., Cho, B.C., Lovly, C.M. and Paz-Ares, L. (2018) Mechanisms of Acquired Resistance to First-and Second-Generation EGFR Tyrosine Kinase Inhibitors. Annals of Oncology, 29, i10-i19.
https://doi.org/10.1093/annonc/mdx703
[56] Choi, Y.L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., et al. (2010) EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. New England Journal of Medicine, 363, 1734-1739.
https://doi.org/10.1056/nejmoa1007478
[57] Shaw, A.T., Friboulet, L., Leshchiner, I., Gainor, J.F., Bergqvist, S., Brooun, A., et al. (2016) Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. New England Journal of Medicine, 374, 54-61.
https://doi.org/10.1056/nejmoa1508887
[58] Xue, J.Y., Zhao, Y., Aronowitz, J., Mai, T.T., Vides, A., Qeriqi, B., et al. (2020) Rapid Non-Uniform Adaptation to Conformation-Specific KRAS(G12C) Inhibition. Nature, 577, 421-425.
https://doi.org/10.1038/s41586-019-1884-x
[59] Ryan, M.B., Fece de la Cruz, F., Phat, S., Myers, D.T., Wong, E., Shahzade, H.A., et al. (2020) Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition. Clinical Cancer Research, 26, 1633-1643.
https://doi.org/10.1158/1078-0432.ccr-19-3523
[60] Ozakinci, H., Desai, B., Kalos, D., Chen, D., Henry, M., Solanki, H., et al. (2026) Pre-Clinical Efficacy of Trastuzumab Deruxtecan Plus Sotorasib in KRASG12C-Mutant Non-Small Cell Lung Cancer and Exploratory HER2 Profiling in Human Tumors. Translational Lung Cancer Research, 15, 94-94.
https://doi.org/10.21037/tlcr-2025-1-1431
[61] Yang, X., Xia, Y., Xu, L., Liang, L., Zhuo, M., Wu, M., et al. (2021) Efficacy and Safety of Combination Treatment with Apatinib and Osimertinib after Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study. Frontiers in Molecular Biosciences, 8, Article 639892.
https://doi.org/10.3389/fmolb.2021.639892
[62] Thiruvalluvan, M., Billet, S., Liu, Z., Lownik, J., Waissengrin, B., Kim, H., et al. (2025) CD105 Blockade Restores Osimertinib Sensitivity in Drug-Resistant EGFR-Mutant Non-Small Cell Lung Cancer. Drug Resistance Updates, 81, Article ID: 101237.
https://doi.org/10.1016/j.drup.2025.101237
[63] Zhang, Y., Wang, C., Zhao, J. and Wang, M. (2024) The Efficacy of Almonertinib and Anlotinib Combination Therapy for Advanced Non‐Small‐Cell Lung Cancer Patients Who Continued to Experience Cancer Progression during Third‐Generation EGFR‐TKI Treatment: A Retrospective Study. Thoracic Cancer, 15, 1757-1763.
https://doi.org/10.1111/1759-7714.15399
[64] Chen, T., Zhang, P., Cong, X., Wang, Y., Li, S., Wang, H., et al. (2024) Synergistic Antitumor Activity of Baicalein Combined with Almonertinib in Almonertinib-Resistant Non-Small Cell Lung Cancer Cells through the Reactive Oxygen Species-Mediated PI3K/Akt Pathway. Frontiers in Pharmacology, 15, Article 1405521.
https://doi.org/10.3389/fphar.2024.1405521
[65] Qi, R., Fu, X., Yu, Y., Xu, H., Shen, M., He, S., et al. (2023) Efficacy and Safety of Re-Challenging 160 mg Furmonertinib for Advanced NSCLC after Resistance to Third-Generation EGFR-TKIs Targeted Agents: A Real-World Study. Lung Cancer, 184, Article ID: 107346.
https://doi.org/10.1016/j.lungcan.2023.107346
[66] Dagogo-Jack, I., Kiedrowski, L.A., Heist, R.S., Lin, J.J., Meador, C.B., Krueger, E.A., et al. (2023) Efficacy and Tolerability of ALK/MET Combinations in Patients with Alk-Rearranged Lung Cancer with Acquired MET Amplification: A Retrospective Analysis. JTO Clinical and Research Reports, 4, Article ID: 100534.
https://doi.org/10.1016/j.jtocrr.2023.100534
[67] Cavazzoni, A., Pagano Mariano, M., Palladini, A., Digiacomo, G., La Monica, S., Bonelli, M., et al. (2026) Targeting HGF/MET and CXCL1/CXCR2 Axes Bypasses Resistance to KRASG12C Inhibitors in NSCLC. Lung Cancer, 213, Article ID: 108939.
https://doi.org/10.1016/j.lungcan.2026.108939
[68] Rosell, R., Jantus-Lewintre, E., Cao, P., Cai, X., Xing, B., Ito, M., et al. (2024) KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC) Therapy Based on Tepotinib and Omeprazole Combination. Cell Communication and Signaling, 22, Article No. 324.
https://doi.org/10.1186/s12964-024-01667-x
[69] Thatikonda, V., Lyu, H., Jurado, S., Kostyrko, K., Bristow, C.A., Albrecht, C., et al. (2024) Co-Targeting SOS1 Enhances the Antitumor Effects of KRASG12C Inhibitors by Addressing Intrinsic and Acquired Resistance. Nature Cancer, 5, 1352-1370.
https://doi.org/10.1038/s43018-024-00800-6
[70] Lin, W., Chen, Q., Yang, Y., Gao, Y. and He, J. (2026) Targeting the Mevalonate Pathway with Statins Overcomes Acquired Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer. Experimental Hematology & Oncology, 15, Article No. 52.
https://doi.org/10.1186/s40164-026-00797-x

为你推荐